Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
HER2
breast cancer
gene expression
molecular intrinsic subtype
paired samples
pathological complete response
residual disease
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
Historique:
received:
21
08
2019
accepted:
11
09
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
[This corrects the article DOI: 10.3389/fonc.2019.00707.].
Identifiants
pubmed: 31598491
doi: 10.3389/fonc.2019.00967
pmc: PMC6773977
doi:
Types de publication
Published Erratum
Langues
eng
Pagination
967Commentaires et corrections
Type : ErratumFor
Informations de copyright
Copyright © 2019 Pernas, Petit, Climent, Paré, Perez-Martin, Ventura, Bergamino, Galván, Falo, Morilla, Fernandez-Ortega, Stradella, Rey, Garcia-Tejedor, Gil-Gil and Prat.